Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Bennett-Guerrero, 2021
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
59/15 inconclusive -18% -23%
COALIZAO ACTION, 2021
 
NCT04394377
RCTanticoagulant, curative dosecontrolCOVID 19 hospitalizedsome concern
311/304 inconclusive 50%
COALIZAO ACTION, 2021
 
NCT04394377
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID 19 hospitalizedsome concern
311/304 inconclusive 50%
CONCOR-1, 2021
 
NCT04348656
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
625/313 safety concern 2% 14%
COV-BARRIER, 2021
 
NCT04421027
RCTbaricitinibplaceboCOVID 19 hospitalizedlow
764/761 suggested -39%
Kirenga, 2021
 
NCT04542941
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
67/69 inconclusive 23%
Mahajan, 2021 RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
41/41 inconclusive 21%
RCT-TCZ-COVID-19, 2021
 
NCT04346355
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
60/66 inconclusive 112%
RECOVERY, 2021
 
NCT04381936
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
2022/2094 conclusif demonstrated-13% -13%
RECOVERY (plasma), 2021
 
NCT04381936
RCTconvalescent plasma treatmentcontrolCOVID 19 hospitalizedsome concern
5795/5763 inconclusive 0% -1%
RECOVERY REGN-COV2, 2021
 
NCT04381936
RCTcasirivimab and imdevimab (REGN-COV2)standard of careCOVID 19 hospitalizedsome concern
4839/4946 conclusif demonstrated-18% -15%
Rutgers, 2021 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
174/180 suggested -34% -32%
Soin AS (COVINTOC), 2021
 
CTRI/2020/05/025369
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
90/90 inconclusive -30%
ACTT-2 (Kalil), 2020
 
NCT04401579
RCTbaricitinibplaceboCOVID 19 hospitalizedlow
515/518 conclusif -32% demonstrated14% -28%
ConCOVID (Gharbharan et al.), 2020
 
NCT04342182
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
43/43 inconclusive -5%
ConPlas-19, 2020
 
NCT04345523
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
179/171 inconclusive -48% -4% -5%
Dongsheng Wang, 2020
 
ChiCTR2000029765
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
33/32 safety concern 123%
EMPACTA, 2020
 
NCT04372186
RCTtocilizumab placeboCOVID 19 hospitalizedsome concern
259/129 conclusif 12% 13% demonstrated-40%
Salman, 2020
 
NCT04530370
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
15/15 inconclusive
SOLIDARITY (remdesivir), 2020
 
NCT04315948
RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
2750/2725 inconclusive -5% -3%
EU-CTR2020-001375-32 (PreToVid) unpublished
 
EU-CTR2020-001375-32
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
174/180 inconclusive -37%
EU-CTR2020-001748-24 (ImmCoVA) unpublished
 
EU-CTR2020-001748-24
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
22/27 inconclusive 23%
NCT04330638 (COV-AID) unpublished
 
NCT04330638
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
81/72 inconclusive 14%
NCT04412772 (ARCHITECTS) unpublished
 
NCT04412772
RCTtocilizumab placeboCOVID 19 hospitalizedlow
10/11 inconclusive -74%
NCT04434717 (COVITOZ-1 single dose plus two doses) unpublished
 
NCT04434717
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
17/9 inconclusive -44%
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg) unpublished
 
NCT04479358
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
20/8 inconclusive -84%
NCT04577534 (COVIDSTORM) unpublished
 
NCT04577534
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
26/13 inconclusive -46%

COVID 19 all comers meta-analysis

BACC Bay Tocilizumab Trial, 2020
 
NCT04356937
RCTtocilizumab placeboCOVID 19 all comerslow
161/81 inconclusive 47% 5% -15%
NIH NIAID ACTT-1, 2020
 
NCT04280705
RCTremdesivirplaceboCOVID 19 all comerssome concern
541/521 suggested -40% 26%

COVID-19 mild to moderate meta-analysis

ATTACC, ACTIV-4a, and REMAP-CAP, noncritically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%
ATTACC, ACTIV-4a, and REMAP-CAP, noncritically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%
GS-US-540-5774, 10 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
197/200 safety concern -22% 14%
GS-US-540-5774, 5 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
199/200 conclusif -44% demonstrated58%
Libster, 2020
 
NCT04479163
RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
80/80 conclusif -45%

COVID-19 severe or critically meta-analysis

CAPSID, 2021
 
NCT04433910
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
53/52 inconclusive -15% 52%
INSPIRATION, 2021
 
NCT04486508
RCTanticoagulation, intermediate prophylactic dosecontrolCOVID-19 severe or criticallysome concern
276/286 inconclusive 8%
INSPIRATION, 2021
 
NCT04486508
RCTanticoagulation, intermediate prophylactic doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
276/286 inconclusive 8%
O’Donnell, 2021
 
NCT04359810
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
150/73 inconclusive -48% 18%
REMAP-CAP plasma, 2021
 
NCT02735707
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
1095/916 safety concern -4%
REMAP-CAP tocilizumab, 2021
 
NCT02735707
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif -27% demonstrated58%
REMAP-CAP, ACTIV-4a, ATTACC, critically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
591/616 inconclusive 7% -15%
REMAP-CAP, ACTIV-4a, ATTACC, critically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
591/616 inconclusive 7% -15%
Rosas (REMDACTA), 2021
 
NCT04409262
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
434/215 inconclusive -5% -2%
Sekine (PLACOVID), 2021
 
NCT04547660
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
80/80 inconclusive 34% -5%
Talaschian, 2021
 
IRCT20081027001411N4
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive 23%
Veiga, 2021
 
NCT04403685
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
65/64 safety concern safety concern153% 49%
AlQahtani, 2020
 
NCT04356534
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive -47%
CAP-China (Wang et al.), 2020
 
NCT04257656
RCTremdesivirplaceboCOVID-19 severe or criticallylow
158/79 inconclusive 9% 21%
CORIMUNO-TOCI-1 (Group 1), 2020
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
64/67 inconclusive -7% -39%
CORIMUNO-TOCI-ICU (Group 2), 2020
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
49/43 inconclusive -32%
COVACTA (Rosas), 2020
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
301/151 safety concern 25% 17%
Li, 2020
 
ChiCTR2000029757
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive -37% 36%
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
228/106 inconclusive -6% -17%
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
228/106 inconclusive -6% -17%

COVID 19 outpatients meta-analysis

C3PO, 2020
 
NCT04355767
RCTconvalescent plasma treatmentplaceboCOVID 19 outpatientssome concern
257/254 inconclusive 88%
Study 2067 2400mg (Weinreich), 2020
 
NCT04425629
RCTcasirivimab and imdevimab (REGN-COV2)placeboCOVID 19 outpatientslow
1355/1341 conclusif
42 studies excluded by filtering options (15 RCT / 27 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).